FDA Approval: Bortezomib (Velcade) for Multiple myeloma

A narrow door, opened in 2003

The FDA letter is dated May 13, 2003. It approved Velcade for one job: treating people with multiple myeloma who had already had at least two prior therapies, and whose disease had progressed on the last one.

The application had been filed on January 21 that year. The review took under four months. FDA granted it under the accelerated approval rules, which the letter states plainly.

A different way to kill a cell

Bortezomib was the first proteasome inhibitor approved for any cancer.

Every cell has a disposal system. Proteins that are damaged or no longer needed get tagged and fed into a shredder called the 26S proteasome. FDA's 2003 label describes this ubiquitin-proteasome pathway as essential to keeping the inside of a cell in order.

Bortezomib blocks the shredder. Waste proteins pile up, signals inside the cell go haywire, and the cell dies. Myeloma cells turn out to be unusually sensitive to this, because they already run their protein factories flat out making antibody. Our page on multiple myeloma explains where those plasma cells come from.

What the trial showed

The evidence was one open-label study of 202 people, all of whom had already been through at least two treatments.

Among the 188 people assessed for response, 52 responded, which is 27.7 percent. Five of those, or 2.7 percent, were complete responses. The rest were partial. Responses took a median of 38 days to appear and lasted a median of 365 days. Median survival for everyone enrolled was 16 months.

Roughly one person in four saw their myeloma shrink after two failed treatments. That was the case for approval.

The sentence the label printed on itself

The 2003 label did not oversell. It stated that the effectiveness of Velcade is based on response rates, and that there were no controlled trials demonstrating a clinical benefit such as an improvement in survival.

That is exactly what accelerated approval means. A drug reaches people early on a measure that stands in for benefit, and the proof of benefit is expected later. Our explainer on clinical trial phases covers why a single-arm study cannot answer the survival question.

Side effects that steer the dose

Two problems dominate.

The first is peripheral neuropathy, which is nerve damage felt as numbness, burning, or tingling in the hands and feet. The 2003 label warns that bortezomib causes it, and that people who already have symptoms may get worse.

The second is thrombocytopenia, a drop in platelets, the cells that let blood clot. The label reports it in about 40 percent of people treated. Low platelets mean bruising, nosebleeds, and a bleeding risk that needs watching.

Both are reasons doses get lowered, delayed, or given under the skin rather than into a vein.

Where the drug ended up

The confirmatory work was done, and the narrow door widened. The current FDA label lists bortezomib for adults with multiple myeloma, with no requirement for prior therapy, and for adults with mantle cell lymphoma. It is now a backbone drug rather than a last resort.

Myeloma by the numbers

The American Cancer Society projects about 36,000 new myeloma cases and 10,850 deaths in the United States in 2026, and SEER carries that projection. Five-year relative survival, measured by NCI from SEER records, is 63.7 percent for people diagnosed between 2016 and 2022, up substantially from the era before this drug. That figure is an average across a disease that behaves very differently from person to person.

Signs that deserve blood and urine tests

NCI lists these signs of multiple myeloma:

• bone pain, especially in the back or ribs.
• bones that break easily.
• fever for no known reason, or frequent infections.
• easy bruising or bleeding.
• trouble breathing.
• weakness of the arms or legs.
• feeling very tired.

Back pain is common and usually not myeloma. What raises concern is back or rib pain that does not settle, especially with anemia, repeated infections, or kidney problems on a blood test. Ask about myeloma directly if a fracture happens after a minor knock. Our guide to multiple myeloma symptoms explains the tests that follow.

What this approval cannot tell you

• The 2003 study had no comparison group. It cannot say whether people lived longer than they would have otherwise.
• Response rate measures shrinkage of disease markers, not how someone feels or how long they live.
• The people studied had already failed two treatments. Results in that setting do not transfer to newly diagnosed disease.
• The label has changed many times since 2003. Current prescribing information governs use today.

Sources

• FDA accelerated approval letter, VELCADE, May 13, 2003
• FDA prescribing information, VELCADE, 2003
• NCI: Velcade and multiple myeloma
• NCI: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ) — Patient Version
• SEER Cancer Stat Facts: Myeloma

How this page was made

An AI-assisted editorial system helped prepare this page. This article has not been reviewed by a healthcare professional unless a named reviewer is specifically shown. Cancer Explained is published by the National Cancer Information Foundation as a nonprofit-oriented public-interest education project. It is not a diagnostic service, does not recommend treatments, and is not for emergencies.

Found an error, a broken source link, outdated information, or wording that feels insensitive? Report it here — we log and act on material corrections.